treatment protocol with drugs and dosage in details for chronic kidney disease in dogs with step by step details of everything
Reading File
Finding Sources
Finding Sources
The library does not contain veterinary-specific textbooks. I'll provide a comprehensive, evidence-based answer from my clinical knowledge of canine CKD management, which is well-established in veterinary internal medicine.
Chronic Kidney Disease (CKD) in Dogs — Complete Treatment Protocol
Staging (IRIS Guidelines — Foundation of All Treatment Decisions)
The International Renal Interest Society (IRIS) staging system is the standard for canine CKD:
| IRIS Stage | Creatinine (mg/dL) | SDMA (µg/dL) | Clinical Signs |
|---|---|---|---|
| Stage 1 | < 1.4 | < 18 | None; early markers only |
| Stage 2 | 1.4 – 2.8 | 18 – 35 | Mild/no signs |
| Stage 3 | 2.9 – 5.0 | 36 – 54 | Moderate signs |
| Stage 4 | > 5.0 | > 54 | Severe uremia |
Sub-staging is mandatory:
- Proteinuria: UPC < 0.2 (non-proteinuric), 0.2–0.5 (borderline), > 0.5 (proteinuric)
- Blood Pressure: Normotensive (< 140 mmHg), borderline (140–159), hypertensive (160–179), severely hypertensive (≥ 180)
Step-by-Step Treatment Protocol
STEP 1 — DIETARY MANAGEMENT (All Stages)
Renal diet is the single most evidence-based intervention in canine CKD.
- Phosphorus restriction: Begin at Stage 2. Target serum phosphorus:
- Stage 2: 2.7–4.5 mg/dL
- Stage 3: 2.7–5.0 mg/dL
- Stage 4: 2.7–6.0 mg/dL
- Protein restriction: Moderate (not severe). High biological value protein; avoid excess that worsens uremia.
- Sodium restriction: Mild-to-moderate; avoid high sodium diets.
- Omega-3 fatty acids: Anti-inflammatory, nephroprotective. Target EPA+DHA ~100 mg/kg/day (fish oil supplementation acceptable).
- Water intake: Encourage via wet food, water fountains. Dehydration worsens CKD.
STEP 2 — PHOSPHORUS MANAGEMENT (Stage 2–4)
If dietary restriction alone does not meet phosphorus targets, add intestinal phosphate binders.
| Drug | Dose | Notes |
|---|---|---|
| Aluminum hydroxide | 30–90 mg/kg/day PO, divided with meals | Most effective; avoid long-term due to aluminum accumulation risk |
| Calcium carbonate | 90–150 mg/kg/day PO with meals | Avoid if hypercalcemia present |
| Lanthanum carbonate (Fosrenol) | 100–200 mg/kg/day PO with meals | Newer; effective but expensive |
| Sevelamer carbonate | 1.6–3.2 g per meal | Non-absorbed polymer; safe, no mineral accumulation |
Key rule: Give binders with food — they bind dietary phosphorus in the gut.
STEP 3 — PROTEINURIA MANAGEMENT
If UPC > 0.5 (confirmed on 2–3 samples), treat to reduce glomerular hypertension and slow progression.
First-line:
| Drug | Dose | Mechanism |
|---|---|---|
| Enalapril (ACE inhibitor) | 0.5 mg/kg PO q12–24h | Reduces efferent arteriolar pressure, decreases proteinuria |
| Benazepril (ACE inhibitor) | 0.5 mg/kg PO q12–24h | Preferred in CKD; partial hepatic excretion; less renal clearance dependency |
Monitoring: Check creatinine and potassium 1–2 weeks after starting. Acceptable creatinine increase ≤ 30% from baseline. Discontinue if severe azotemia worsens.
Second-line (if ACE-I insufficient or not tolerated):
| Drug | Dose | Notes |
|---|---|---|
| Telmisartan (ARB) | 1 mg/kg PO q24h | Angiotensin receptor blocker; excellent for proteinuria; now preferred by many internists |
| Amlodipine | 0.1–0.3 mg/kg PO q24h | Add if hypertension co-exists |
STEP 4 — HYPERTENSION MANAGEMENT
Target BP: < 160 mmHg (ideally < 140 mmHg)
| Drug | Dose | Class | Notes |
|---|---|---|---|
| Amlodipine | 0.1–0.25 mg/kg PO q24h | Calcium channel blocker | First-line in dogs; well tolerated |
| Telmisartan | 1 mg/kg PO q24h | ARB | First-line if proteinuria also present |
| Benazepril/Enalapril | 0.5 mg/kg PO q12–24h | ACE inhibitor | Add as second agent if needed |
| Hydralazine | 0.5–2 mg/kg PO q12h | Vasodilator | Rarely needed; reserve for refractory cases |
Monitoring: BP recheck 1–2 weeks after dose change, then every 1–3 months.
STEP 5 — ANEMIA MANAGEMENT (Stage 3–4)
Non-regenerative anemia from reduced erythropoietin (EPO) production. Treat when PCV < 20–25% with clinical signs.
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Darbepoetin alfa (Aranesp) | 1 µg/kg SC q7 days until PCV reaches 35–40%, then reduce to q14–21 days | SC | Preferred over recombinant EPO; lower immunogenicity |
| Epoetin alfa (rHuEPO) | 100 U/kg SC 3x/week until target PCV, then reduce | SC | Risk of anti-EPO antibody formation (pure red cell aplasia) — monitor |
| Iron supplementation | Ferrous sulfate 100–300 mg/dog PO q24h, OR iron dextran 50 mg IM once | PO/IM | Essential alongside ESA therapy; iron deficiency blunts response |
Monitoring: PCV weekly until stable. Stop ESA if PCV > 50% (polycythemia risk). Watch for hypertension as a side effect.
STEP 6 — METABOLIC ACIDOSIS (Stage 3–4)
Target: Bicarbonate/TCO₂ > 18 mEq/L (ideally 18–24).
| Drug | Dose | Notes |
|---|---|---|
| Sodium bicarbonate | 8–12 mg/kg PO q8–12h | Titrate to response; avoid sodium loading in hypertension |
| Potassium citrate | 40–75 mg/kg/day PO divided q8–12h | Preferred if concurrent hypokalemia; alkalinizing + potassium replacement |
STEP 7 — NAUSEA, VOMITING & UREMIC GASTROPATHY (Stage 3–4)
Uremia causes gastric acid hypersecretion and nausea. Treat proactively.
| Drug | Dose | Indication |
|---|---|---|
| Omeprazole | 0.5–1 mg/kg PO q24h | Gastric acid suppression (PPI — preferred) |
| Famotidine | 0.5 mg/kg PO/IV q12–24h | H2 blocker; less effective than PPI in uremia |
| Maropitant (Cerenia) | 2 mg/kg PO q24h OR 1 mg/kg SC q24h | Antiemetic — NK1 receptor antagonist; excellent for uremic nausea |
| Ondansetron | 0.5–1 mg/kg PO/IV q12–24h | 5-HT3 antagonist; adjunct antiemetic |
| Metoclopramide | 0.2–0.5 mg/kg PO/SC q8h | Prokinetic + antiemetic; avoid if GI obstruction |
STEP 8 — HYPOKALEMIA (Common in CKD, Especially Stages 2–4)
Potassium wasting from polyuria. Target serum K⁺: 3.5–5.5 mEq/L.
| Drug | Dose | Notes |
|---|---|---|
| Potassium gluconate (Tumil-K) | 2–4 mEq/cat/dog per day PO, titrate | First-line oral supplementation |
| Potassium citrate | 40–75 mg/kg/day PO | Dual purpose: alkalinizing + K⁺ replacement |
| IV KCl (hospitalized patients) | 0.5 mEq/kg/hr max IV rate; add to IV fluids | For severe hypokalemia (< 2.5 mEq/L) with weakness |
STEP 9 — FLUID THERAPY
Outpatient (Stage 2–3): Encourage oral hydration (wet food, water fountain).
Subcutaneous fluids (Stage 2–4, chronic):
- Lactated Ringer's Solution or 0.9% NaCl: 75–150 mL SC q24–48h at home
- Provides volume to support GFR and reduce uremic toxin accumulation
- Owner-administered; significantly improves quality of life
Inpatient (acute-on-chronic, uremic crisis):
- IV fluid diuresis: LRS at 2–3× maintenance (4–6 mL/kg/hr) for 24–48h
- Reassess creatinine, hydration, urine output
- Transition to maintenance rate (2 mL/kg/hr) once rehydrated
STEP 10 — SECONDARY HYPERPARATHYROIDISM (Stage 2–4)
Elevated PTH from hyperphosphatemia and low calcitriol.
| Drug | Dose | Notes |
|---|---|---|
| Calcitriol (active Vit D) | 1.5–3.5 ng/kg PO q24h (very low dose) | Reduces PTH; ONLY start after phosphorus controlled (< 6 mg/dL); risk of hypercalcemia/hyperphosphatemia if given prematurely |
Monitoring: Ionized calcium monthly when on calcitriol. Discontinue if hypercalcemia occurs.
STEP 11 — SYSTEMIC INFLAMMATION & FIBROSIS (Adjunctive)
| Drug | Dose | Notes |
|---|---|---|
| Omega-3 fatty acids | EPA+DHA ~100–200 mg/kg/day PO | Anti-inflammatory, anti-fibrotic; fish oil supplements |
| Antioxidants (Vit E, C) | Vit E 400–800 IU/day; Vit C 100–200 mg/day | Reduce oxidative stress in uremia; evidence moderate |
Monitoring Schedule
| Parameter | Stage 2 | Stage 3 | Stage 4 |
|---|---|---|---|
| Creatinine / BUN / SDMA | Every 3–6 months | Every 2–3 months | Every 1–2 months |
| Phosphorus | Every 3–6 months | Every 2–3 months | Every 1–2 months |
| Electrolytes (K⁺, Na⁺, HCO₃⁻) | Every 6 months | Every 3 months | Every 1–2 months |
| UPC (proteinuria) | Every 3–6 months | Every 3 months | Every 1–2 months |
| Blood pressure | Every 6 months | Every 3 months | Every 1–2 months |
| CBC (PCV for anemia) | Every 6 months | Every 3 months | Every 1–2 months |
| Body weight / BCS | Every visit | Every visit | Every visit |
| Urinalysis + culture | Annually | Every 6 months | Every 3–6 months |
Summary Table — Drugs by Indication
| Problem | Drug | Dose |
|---|---|---|
| Phosphorus control | Aluminum hydroxide | 30–90 mg/kg/day with meals |
| Phosphorus control | Lanthanum carbonate | 100–200 mg/kg/day with meals |
| Proteinuria | Benazepril | 0.5 mg/kg PO q12–24h |
| Proteinuria | Telmisartan | 1 mg/kg PO q24h |
| Hypertension | Amlodipine | 0.1–0.25 mg/kg PO q24h |
| Anemia | Darbepoetin alfa | 1 µg/kg SC q7d (loading) |
| Acidosis | Potassium citrate | 40–75 mg/kg/day PO |
| Nausea/vomiting | Maropitant | 2 mg/kg PO q24h |
| Gastric acid | Omeprazole | 0.5–1 mg/kg PO q24h |
| Hypokalemia | Potassium gluconate | 2–4 mEq/day PO |
| Low PTH / Vit D | Calcitriol | 1.5–3.5 ng/kg PO q24h |
Important Clinical Notes
- Avoid nephrotoxic drugs: NSAIDs (meloxicam, carprofen), aminoglycosides, contrast agents, and ACE inhibitors in severely dehydrated patients.
- Telmisartan vs. Benazepril: Recent evidence (including the IRENID study) shows telmisartan may be superior for both proteinuria reduction and renal protection.
- Do not over-restrict protein in dogs (unlike cats) — it causes muscle wasting. Moderate restriction with high biological value protein is optimal.
- Calcitriol timing: Never start before phosphorus is well controlled — it will worsen hyperphosphatemia and soft tissue mineralization.
- Concurrent UTI: Common in CKD dogs due to dilute urine. Culture urine at diagnosis and every 6 months; treat with culture-guided antibiotics if positive.
This is a shared conversation. Sign in to Orris to start your own chat.